Sareum Share News (SAR)
SAR Share
SAR Share
SAR Share
SAR Share
SAR
SAR Share
SAR Level 2
SAR Live
SAR Broker
SAR Directors
SAR Financial
SAR
SAR Short
SAR
Last checked at -
(Alliance News) - Sareum Holdings PLC on Thursday said it has been focusing on toxicology studies in its development of drug candidates SDC-1801 and SDC-1802 with a view to CONDUCT human trials in
Read moreLONDON (Alliance News) - Sareum Holdings PLC on Monday said it noted its licensee Sierra Oncology's webcast discussing clinical findings and possible next steps for SRA737, its oral checkpoint
Read moreLONDON (Alliance News) - Sareum Holdings PLC on Monday said that Sierra Oncology reported positive preliminary clinical data from two in-human studies of SRA737.Shares in the drug company a
Read moreLONDON (Alliance News) - Cancer drug discovery firm Sareum Holdings PLC said Monday its interim loss widened as costs rose, but it made progress with its key developmental programmes.For to
Read more
(Sharecast News) - Sareum Holdings' shares dropped on Monday after the company reported a widened interim loss due to rising costs, though it stated progress had been made with key development programmes.
Read more(Sharecast News) - Specialist small molecule drug development company Sareum Holdings announced on Thursday that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, had reported that an abstract reporting preclinical data for SRA737 - its Chk1 inhibitor - plus low dose gemcitabine (LDG), in combination with immunotherapy, had been selected for a late-breaking oral presentation at the American Association of Cancer Research annual meeting.
Read moreWednesday 12 DecemberBlancco Technology GroupBellwayVolution Shopping REIT (re voluntary 13 Asian 14 to
Read moreLONDON (Alliance News) - Sareum Holdings PLC said Friday that Sierra Oncology Inc reported preclinical efficacy data for an immunotherapy combination with its SRA737 inhibitor in lung licences the
Read moreLONDON (Alliance News) - Sareum Holdings PLC said Friday it raised GBP850,000 via the issue of 130.8 million shares to fund the development of its lead cancer and autoimmune drugs.The drug
Read more(Sharecast News) - Drug maker Sareum has raised £850,000 to progress the development programme of its cancer inhibitor TYK2/JAK1.
Read moreLONDON (Alliance News) - Sareum Holdings PLC on Monday said it swung to an annual loss after reporting a substantial share of profit from associates the year before.Shares in Sareum were at
Read more(Sharecast News) - Drug discovery and development company Sareum Holdings has made the formal selection of a development candidate from its TYK2 inhibitor programme to advance through preclinical development as a potential new targeted therapy for certain cancers, it announced on Wednesday.
Read moreLONDON (Alliance News) - Sareum Holdings PLC said Wednesday that it has selected the SDC-1802 molecule from the TYK2 inhibitor programme for further development as potential treatment for certain
Read moreLONDON (Alliance News) - Sareum Holdings PLC said Tuesday it expects to report a loss in its annual results as it progresses on its programmes in autoimmune diseases and cancer.The drug it
Read moreLONDON (Alliance News) - Sareum Holdings PLC said Monday it will develop SDC-1801 as a possible treatment for autoimmune diseases.The molecule, SDC-1801, has been formally selected for is a
Read more
Last checked at